IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025

Core Points - IMUNON, Inc. is a clinical-stage biotechnology company focused on DNA-mediated immunotherapy, currently in Phase 3 development with its lead product, IMNN-001, for advanced ovarian cancer [1][5] - The company will host a conference call on November 13, 2025, to discuss its third-quarter financial results and provide updates on its clinical development programs [1][2] Company Overview - IMUNON is advancing innovative treatments that utilize the body's natural mechanisms to generate effective responses against various diseases, differentiating itself from conventional therapies [4] - The company is developing non-viral DNA technology, with two main modalities: TheraPlas for gene-based delivery of cytokines in solid tumors, and PlaCCine for gene delivery of viral antigens [4] Clinical Development - IMNN-001 is designed for localized treatment of advanced ovarian cancer and has completed multiple clinical trials, including a Phase 2 trial (OVATION 2) and is currently in a Phase 3 trial (OVATION 3) [5] - The therapy instructs the body to produce cancer-fighting molecules like interleukin-12 and interferon gamma at the tumor site [5] - The company has also completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101) [5]